DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)" report to their offering.
Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021) provides a detailed analysis of the global hereditary market with analysis of market size by value, growth, segments, etc.
The global hereditary angioedema market is projected to increase at a healthy rate during the forecasted period (2017-2021). This growth is expected on account of many growth drivers such as increased diagnosis in the US and Europe, advantages of preventive therapy, approval of Berinert for pediatric treatment, launch of Haegarda C1 inhibitor and some other major products in the pipeline.
However, the market also faces certain challenges such as high prophylaxis cost, side effects of Cinryze and long-term prophylactic treatment. Oral therapy for hereditary angioedema attacks and SHP643 monoclonal antibody are some of the trends in the global hereditary angioedema market.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global hereditary angioedema market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Shire Plc, iBio, Inc., Pharming Group NV and CSL Limited are some of the key players operating in the global hereditary angioedema market whose company profiling is done in the report. In this segment of the report, business overview, financial overview and the business strategies of the companies are provided.
- Increasing Diagnosis in US and Europe
- Advantages of Preventive Therapy
- Approval of Berinert for Pediatric Treatment
- Launch of Haegarda C1 inhibitor
- Other Major Products in Pipeline
- High Prophylaxis Cost
- Side Effects of Cinryze
- Side Effects of Long-Term Prophylactic Treatment
- Misdiagnosis of the Disorder
- Oral Therapy for HAE Attacks
- SHP643 Monoclonal Antibody
- Shire Plc
- iBio, Inc.
- Pharming Group NV
- CSL Limited
Key Topics Covered:
1. Executive Summary
3. Global Market Analysis
4. Regional Analysis
5. Market Dynamics
6. Competitive Landscape
7. Company Profiling
For more information about this report visit http://www.researchandmarkets.com/research/b43xg4/global_hereditary